Market Trends of Global Anesthesia Gases Industry
Isoflurane Gas is Expected to Witness Significant Growth Over The Forecast Period
Isoflurane is commonly used for induction and maintenance of general anesthesia in the operating room. The increasing number of emergency departments and surgical interventions and the rising geriatric population prone to chronic diseases are expected to drive the segment growth.
According to an article updated by NCBI in August 2022, isoflurane is a volatile anesthetic gas approved by the FDA for the induction and maintenance of general anesthesia, and unlike other common anesthesia gases, isoflurane is a non-flammable volatile anesthetic gas. The source also stated that with regards to cardiac function, isoflurane has minimal impact on left ventricular function, but it does cause a dose-dependent decrease in systemic vascular resistance due to mild beta-adrenergic stimulation. Thus, the increasing advantages of isoflurane are expected to boost segment growth.
Companies offering products are innovating and launching new products and engaging in business expansion initiatives such as mergers and acquisitions, collaborations, and partnerships. For instance, in January 2022, the company Dechra Pharmaceuticals acquired Isoflurane USP from Halocarbon Life Sciences. This indicates the demand for isoflurane among pharmaceutical companies. These activities are further expected to augment the growth of the isoflurane segment during the forecast period of study.
Thus, the adoption of isoflurane gas is expected to increase during the forecast period of study due to the above-mentioned factors, such as the increasing number of emergency department cases and surgical interventions and the rising geriatric population prone to chronic diseases.
North America is Expected to Hold a Significant Share in the Anesthesia Gases Market Over The Forecast Period
North America is expected to hold a significant share of the overall market, throughout the forecast period. This is due to the rising geriatric population and increased surgical procedures in the region.
According to the National Spinal Cord Injury Statistical Center in 2022, about 30% of persons with spinal cord injury (SCI) are re-hospitalized one or more times during any given year following injury, and among those re-hospitalized, the length of hospital stay averages about 18 days in the United States. Hence, due to the rising number of spinal cord injuries in the United States, spinal cord surgeries are also expected to increase, leading to more usage of anesthesia gases.
Moreover, the rising incidence of spinal cord injury in Canada is also expected to enhance the market growth in the region. For instance, according to an article published by frontiers in November 2022, it is estimated that in Canada more than 86,000 people are affected by spinal cord injuries every year, from either a traumatic (e.g., fall) or non-traumatic injury (e.g., tumor).
Therefore, owing to the above-mentioned factors such as the rising geriatric population and increased surgical procedures, the growth of the studied market is anticipated in the North America Region.
